Paradigm Biopharmaceuticals Ltd has released a press release.
Ipps significant oa pain reduction at 12 months
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- 2023 Annual Report and Appendix 4E
- PAR Reports Phase 3 Clinical Trial Update
- Primary and Secondary endpoints met in MPS I Trial
- iPPS shows 3-year equivalent durability in OA Canine Study
- iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
Later from Paradigm Biopharmaceuticals
- iPPS Increases Cartilage Thickness in Phase 2 Trial
- Paradigm Launches $30M Capital Raising
- Investor Presentation - $30m Capital Raise
- Entitlement Offer and Placement Prospectus
- PAR Successful Placement and Fully Underwritten ANREO
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals